| | Univariate model | Multivariable model |
|---|
Biomarker | OR (95%CI) | Pfdr | OR (95%CI) | Pfdr |
|---|
Total NT-proBNP | 1.70 (1.32–2.19) | 7.4 × 10–5 | 1.58 (1.21–2.07) | 0.001 |
NT-proBNP | 2.19 (1.66–2.88) | 1.2 × 10–7 | 2.02 (1.52–2.70) | 8.0 × 10–6 |
Ang2 | 1.43 (1.13–1.82) | 0.004 | 1.32 (1.02–1.71) | 0.034 |
BMP10 | 1.60 (1.23–2.09) | 6.0 × 10–4 | 1.56 (1.19–2.04) | 0.001 |
- The association between biomarker concentration and AF during clinical visits was assessed by means of logistic regression models. The biomarker concentration was the value while AF was ongoing (i.e. if a patient presented AF at the six-month visit, the corresponding biomarker value was included while if the AF was present at 12 months that value was included). If no AF arose during visits, the baseline value was inserted. Data shown as odds ratio (OR) for an increment of 1 SD of baseline
- Multivariable model was adjusted for: heart failure, LVEF < 40% or both, history of hypertension and AF episode with LA dilatation. P-value was corrected for multiple testing by means of FDR-correction
- NT-proBNP, N-terminal pro-B type natriuretic peptide; Ang2, angiopoietin 2; BMP10, bone morphogenic protein-10
